| Autor: |
Martorana F; Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy., Di Grazia G; Department of Human Pathology 'G. Barresi', University of Messina, 98131 Messina, Italy., Rosano GN; Department of Medical, Surgical Sciences and Advanced Technologies 'G.F. Ingrassia', Anatomic Pathology, University of Catania, 95123 Catania, Italy., Vecchio GM; Department of Medical, Surgical Sciences and Advanced Technologies 'G.F. Ingrassia', Anatomic Pathology, University of Catania, 95123 Catania, Italy., Conti C; Department of Human Pathology 'G. Barresi', University of Messina, 98131 Messina, Italy., Nucera S; Department of Human Pathology 'G. Barresi', University of Messina, 98131 Messina, Italy., Magro G; Department of Medical, Surgical Sciences and Advanced Technologies 'G.F. Ingrassia', Anatomic Pathology, University of Catania, 95123 Catania, Italy., Vigneri P; Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.; Humanitas Istituto Clinico Catanese, University Oncology Department, 95045 Catania, Italy. |
| Abstrakt: |
Triple-negative breast cancer (TNBC) represents about 15% of all breast cancers and is usually characterized by aggressive clinical behavior and a poor prognosis. Four TNBC subgroups have been previously defined with different molecular profiles: (i) luminal androgen receptor (LAR), (ii) mesenchymal (MES), (iii) basal-like immunosuppressed (BLIS) and (iv) basal-like immune-activated (BLIA). Among these, LAR is characterized by the expression of the androgen receptor (AR), and exhibits genomic characteristics that resemble luminal breast cancers, with a still undefined prognosis and clinical behavior. Here, we report a case of a woman affected by recurring LAR TNBC, which underwent phenotypic changes throughout its natural history. After the initial diagnosis of LAR breast cancer, the patient experienced local recurrence with strong expression of the estrogen receptor. Due to this finding, she started treatment with a CDK4/6-inhibitor and an aromatase inhibitor, followed by oral vinorelbine, both with dismal outcomes. Then, she received everolimus and exemestane, which determined temporary disease stabilization. An extensive NGS analysis of tumor tissue showed PIK3CA and HER2 mutations. Our case is consistent with previous reports of LAR breast cancer and underlines the potential utility of re-biopsy and molecular testing in breast cancer (BC), especially in rare subtypes. |
